Document is current
Any future updates will be listed below
-
Authors
Hosokawa, Kana
Ikezawa, Kenji
Kai, Yugo
Takada, Ryoji
Kinomoto, Takumi
Masumoto, Takanori
Kawabata, Masaki
Kishimoto, Hiroki
Kozumi, Kazuhiro
Urabe, Makiko
Mukai, Kaori
Nakabori, Tasuku
Ohkawa, Kazuyoshi
- License Information
-
More Information
Article History
Accepted: 27 August 2025
First Online: 12 September 2025
Declarations
:
: This study was approved by the Institutional Review Board of the Osaka International Cancer Institute (Approval No.: 18225-11) and conducted following the ethical principles of the 1964 Declaration of Helsinki and its subsequent amendments. Informed consent to participate in the study was waived in accordance with the Japanese government’s Ethical Guidelines for Medical and Health Research Involving Human Subjects, which allow an opt-out approach for studies based on existing, anonymized information that do not include human biological specimens.
: Kenji Ikezawa reports honoraria for lectures from Taiho Pharmaceutical, Incyte Biosciences Japan, AstraZeneca, MSD, Nihon Servier, Chugai Pharmaceutical, Guardant Health Japan, Eisai and Myriad Genetics and research funding from ASKA Pharmaceutical. Yugo Kai reports honoraria for lectures from Incyte Biosciences Japan. Ryoji Takada reports honoraria for lectures from Taiho Pharmaceutical, Hisamitsu Pharmaceutical, Novartis, MSD, Myriad Genetics and TEIJIN PHARMA. Kazuyoshi Ohkawa reports honoraria for lectures from Chugai Pharmaceutical, Eisai, AstraZeneca, Incyte Biosciences Japan and Nihon Servier, and research grants from Sumitomo Chemical. The other authors have no conflict of interest.
